T. Rowe Price Associates
CLPT icon

T. Rowe Price Associates’s ClearPoint Neuro CLPT Stock Holding History

T. Rowe Price Associates’s Portfolio CLPT Stock Details CLPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$622K Buy
34,856
+5,237
+18% +$65.4K ﹤0.01% 2520
2026
Q1 		$270K Buy
29,619
+2,828
+11% +$35.7K ﹤0.01% 2734
2025
Q4 		$367K Buy
26,791
+1,204
+5% +$22.3K ﹤0.01% 2537
2025
Q3 		$558K Buy
25,587
+1,132
+5% +$13.3K ﹤0.01% 2320
2025
Q2 		$292K Buy
24,455
+10,955
+81% +$138K ﹤0.01% 2544
2025
Q1 		$161K Sell
13,500
-4,200
-24% -$65.3K ﹤0.01% 2713
2024
Q4 		$273K Hold
17,700
– – ﹤0.01% 2547
2024
Q3 		$199K Hold
17,700
– – ﹤0.01% 2658
2024
Q2 		$96K Sell
17,700
-7,167
-29% -$41.5K ﹤0.01% 2765
2024
Q1 		$170K Buy
24,867
+1,813
+8% +$12.7K ﹤0.01% 2665
2023
Q4 		$157K Buy
23,054
+688
+3% +$3.89K ﹤0.01% 2613
2023
Q3 		$113K Hold
22,366
– – ﹤0.01% 2636
2023
Q2 		$162K Buy
22,366
+4,666
+26% +$39.7K ﹤0.01% 2591
2023
Q1 		$150K Buy
17,700
+3,700
+26% +$32.4K ﹤0.01% 2593
2022
Q4 		$119K Buy
+14,000
New +$133K ﹤0.01% 2680
2022
Q2 		– Sell
-10,192
Closed -$106K – 2970
2022
Q1 		$106K Buy
+10,192
New +$92.8K ﹤0.01% 2834

Other funds holding CLPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
CFM
Compass Financial Management Tampa, Florida $829M AUM

T. Rowe Price Associates's CLPT Position: Q2 2026 in Review

T. Rowe Price Associates increased its ClearPoint Neuro (CLPT) stake by 18% in Q2 2026, buying an estimated $65.4K and bringing the position to 34,856 shares worth $622K. The position accounts for ﹤0.01% of the portfolio, ranked #2520.

T. Rowe Price Associates first reported a position in CLPT in Q1 2022 and has held it in 16 quarters since. 129 funds tracked by Wall St. Rank hold CLPT as of Q2 2026.

  • T. Rowe Price Associates held 34,856 shares of ClearPoint Neuro worth $622K as of Q2 2026.
  • T. Rowe Price Associates bought 5,237 ClearPoint Neuro shares in Q2 2026, an estimated $65.4K.
  • ClearPoint Neuro made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2520 holding.
  • T. Rowe Price Associates first reported a position in ClearPoint Neuro in Q1 2022 and has held it in 16 quarters since.
  • 129 funds tracked by Wall St. Rank held ClearPoint Neuro as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.